tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Barcus, 36 are a BUY (94.74%), 2 are a HOLD (5.26%).
Analyst Matthew Barcus, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 60.61% that have a potential upside of 67.58% achieved within 249 days.
Matthew Barcus’s has documented 70 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on QURE, Uniqure NV at 21-Jun-2023.
Analyst best performing recommendations are on IMVT (IMMUNOVANT).
The best stock recommendation documented was for IMVT (IMMUNOVANT) at 9/29/2022. The price target of $12 was fulfilled within 36 days with a profit of $6.62 (123.05%) receiving and performance score of 34.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 12-Feb-2026
$40
$18.59 (86.83%)
$40
22 days ago
(10-Sep-2026)
0/2 (0%)
$15.03 (60.19%)
Buy Since 19-Dec-2023
$35
$13.59 (63.48%)
$31
1 months 20 days ago
(12-Aug-2026)
1/9 (11.11%)
$7.01 (25.04%)
20
Buy Since 08-Nov-2024
$30
$8.59 (40.12%)
$33
6 months 28 days ago
(04-Mar-2026)
0/4 (0%)
$7.48 (33.21%)
Buy Since 05-Sep-2025
$36
$14.59 (68.15%)
$33
6 months 28 days ago
(04-Mar-2026)
1/3 (33.33%)
$13.48 (59.86%)
150
Buy Since 22-Aug-2025
$40
$18.59 (86.83%)
$18
9 months 16 days ago
(16-Dec-2025)
1/2 (50%)
$16.52 (70.36%)
87
What Year was the first public recommendation made by Matthew Barcus?
